Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
266
Views
2
CrossRef citations to date
0
Altmetric
Original Research

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects

Hongjie Qian1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Qian Chen1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Liyu Liang1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Yang Zou1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Huahua Pu1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Liang Xin1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Rong Song1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Tingting Li1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Huijuan Zhu1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Yu Wang3 CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, People’s Republic of ChinaView further author information
,
Guanghui Tian4 Vigonvita Life Science Co., Ltd., Suzhou, 215123, People’s Republic of ChinaView further author information
,
Jingshan Shen2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of China;3 CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9679-9934View further author information
ORCID Icon,
Hualiang Jiang2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of China;3 CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, People’s Republic of ChinaView further author information
,
Chen Yu1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaView further author information
,
Zhen Wang2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of China;3 CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9450-2260View further author information
ORCID Icon &
Jingying Jia1 Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 200031, People’s Republic of China;2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, 200031, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2492-3219View further author information
ORCID Icon show all
Pages 2947-2959 | Published online: 06 Jul 2021

References

  • SchermulyRT, GhofraniHA, WilkinsMR, GrimmingerF. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8:443–455. doi:10.1038/nrcardio.2011.8721691314
  • HumbertM, GuignabertC, BonnetS, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53:1801887. doi:10.1183/13993003.01887-201830545970
  • GalièN, CorrisPA, FrostA, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25):D60–D72. doi:10.1016/j.jacc.2013.10.03124355643
  • GalièN, GhofraniHA, TorbickiA, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–2157. doi:10.1056/NEJMoa05001016291984
  • GalièN, BrundageBH, GhofraniHA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894–2903. doi:10.1161/CIRCULATIONAHA.108.83927419470885
  • PulidoT, AdzerikhoI, ChannickRN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–818. doi:10.1056/NEJMoa121391723984728
  • MakowskiCT, RissmillerRW, BullingtonWM. Riociguat: a novel new drug for treatment of pulmonary hypertension. Pharmacotherapy. 2015;35(5):502–519. doi:10.1002/phar.159226011143
  • ZhengW, WangZ, JiangXR, ZhaoQJ, ShenJS. Targeted drugs for treatment of pulmonary arterial hypertension: past, present, and future perspectives. J Med Chem. 2020;63(24):15153–15186. doi:10.1021/acs.jmedchem.0c0109333314936
  • MoncadaS, HiggsA. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27):2002–2012. doi:10.1056/NEJM1993123032927067504210
  • RabeKF, TenorH, DentG, SchudtC, NakashimaM, MagnussenH. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994;266:L536–L543. doi:10.1152/ajplung.1994.266.5.L5367515580
  • JerniganNL, RestaTC. Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation. Am J Physiol Lung Cell Mol Physiol. 2002;282:L1366–L1375. doi:10.1152/ajplung.00273.200112003794
  • WhartonJ, StrangeJW, MollerGMO, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172(1):105–113. doi:10.1164/rccm.200411-1587OC15817798
  • WangZ, JiangXR, ZhangXL, et al. Pharmacokinetic-driven optimization of 4(3H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension. J Med Chem. 2019;62(10):4979–4990. doi:10.1021/acs.jmedchem.9b0012331021628
  • ZhangMQ, LiuHM, HeJJ, et al. Liquid chromatography-tandem mass spectrometric assay for TPN171 in human plasma. J Pharm Biomed Anal. 2020;191:113634. doi:10.1016/j.jpba.2020.11363432987249
  • Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2002. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/food-effect-bioavailability-and-fed-bioequivalence-studies. Accessed July 02, 2021.
  • GuptaM, KovarA, MeibohmB. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol. 2005;45:987–1003. doi:10.1177/009127000527684716100293
  • NicholsDJ, MuirheadGJ, HarnessJA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53(Suppl1):5S–12S. doi:10.1046/j.0306-5251.2001.00027.x11879254
  • BrockGB. Tadalafil: a new agent for erectile dysfunction. Can J Urol. 2003;10(Suppl 1):17–22.12625846
  • BischoffE. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16:S11–S14. doi:10.1038/sj.ijir.390120815224129
  • VIAGRA® (sildenafil citrate) tablets [prescribing information]. U.S.; December, 2017. 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.